Humanigen

$15.30
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.56 (-3.55%) Today
+$0.09 (+0.59%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Humanigen and other stocks, options, and ETFs commission-free!

About HGEN

Humanigen, Inc. Common Stock, also called Humanigen, is a clinical-stage biopharmaceutical company. It engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA. The listed name for HGEN is Humanigen, Inc. Common Stock.

CEO
Cameron Durrant
Employees
2
Headquarters
Burlingame, California
Founded
2000
Market Cap
820.93M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
875.08K
High Today
$17.21
Low Today
$13.97
Open Price
$17.10
Volume
1.15M
52 Week High
$33.95
52 Week Low
$1.75

HGEN Earnings

-$0.16
-$0.11
-$0.05
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 15, Pre-Market

You May Also Like

ACSG
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure